Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Fenner

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Developmental Biology|September 14, 2000
X inactivation in the mouse embryo deficient for Dnmt1: distinct effect of hypomethylation on imprinted and random X inactivationT Sado, M H Fenner, S S Tan, et al.
International Journal of Clinical Pharmacology and Biopharmacy|April 1, 1975
Cardiovascular side effects of tricyclic antidepressants - a risk in the use of these drugsG Biamino, H Fenner, K P Schüren, et al.
Fundamental & Clinical Pharmacology|January 1, 1989
Blood distribution of tenoxicam in humans: a particular HSA drug interactionF Bree, P Nguyen, S Urien, et al.
Experimental Cell Research|July 31, 1998
Regulation of expression of MSG1 melanocyte-specific nuclear protein in human melanocytes and melanoma cellsH Li, N U Ahmed, M H Fenner, et al.
Blood|January 13, 2006
Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18Hongyu Liu, Chuanbing Zang, Martin H Fenner, et al.
Genomics|August 29, 1998
MSG1 (melanocyte-specific gene 1): mapping to chromosome Xq13.1, genomic organization, and promoter analysisM H Fenner, J E Parrish, Y Boyd, et al.
The Journal of Rheumatology|May 22, 2001
Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapiesT G Woodworth, D E Furst, V Strand, et al.
Leukemia Research|April 28, 2004
Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemiaChuanbing Zang, Hongyu Liu, Maximilian G Posch, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 26, 1998
Transcriptional activating activity of Smad4: roles of SMAD hetero-oligomerization and enhancement by an associating transactivatorT Shioda, R J Lechleider, S L Dunwoodie, et al.
Journal of Neuro-Oncology|December 23, 2003
Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomasChuanbing Zang, Marlies Wächter, Hongyu Liu, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Developmental Biology|September 14, 2000
X inactivation in the mouse embryo deficient for Dnmt1: distinct effect of hypomethylation on imprinted and random X inactivationT Sado, M H Fenner, S S Tan, et al.
International Journal of Clinical Pharmacology and Biopharmacy|April 1, 1975
Cardiovascular side effects of tricyclic antidepressants - a risk in the use of these drugsG Biamino, H Fenner, K P Schüren, et al.
Fundamental & Clinical Pharmacology|January 1, 1989
Blood distribution of tenoxicam in humans: a particular HSA drug interactionF Bree, P Nguyen, S Urien, et al.
Experimental Cell Research|July 31, 1998
Regulation of expression of MSG1 melanocyte-specific nuclear protein in human melanocytes and melanoma cellsH Li, N U Ahmed, M H Fenner, et al.
Blood|January 13, 2006
Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18Hongyu Liu, Chuanbing Zang, Martin H Fenner, et al.
Genomics|August 29, 1998
MSG1 (melanocyte-specific gene 1): mapping to chromosome Xq13.1, genomic organization, and promoter analysisM H Fenner, J E Parrish, Y Boyd, et al.
The Journal of Rheumatology|May 22, 2001
Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapiesT G Woodworth, D E Furst, V Strand, et al.
Leukemia Research|April 28, 2004
Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemiaChuanbing Zang, Hongyu Liu, Maximilian G Posch, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 26, 1998
Transcriptional activating activity of Smad4: roles of SMAD hetero-oligomerization and enhancement by an associating transactivatorT Shioda, R J Lechleider, S L Dunwoodie, et al.
Journal of Neuro-Oncology|December 23, 2003
Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomasChuanbing Zang, Marlies Wächter, Hongyu Liu, et al.
Pageof 8